Incentive-paid items for generic substitution fell to 12,757

The HIRA has released medicines subject to incentive payments on benefit basis

12,757 items were found to be eligible for incentives of 30% of the difference in drug prices if pharmacies dispense generic substitution, which is cheaper than prescription drugs.

 

It decreased 48 items compared to the previous month.

 

The HIRA recently guided the 'Billing Method of Drugs Subjected to Incentives for low-price generic substitution in August'.

 

As of August, 25,745 items were listed on the drug benefits, with 49.5% of the drugs available for generic substitution.

 

Among Metformine and Ranitidines, 203 items of drug sales and suspension are excluded from incentive payments.

 

The generic substitution to low-cost drugs is a system that allows pharmacies to get back 30% of the difference in drug prices.

 

If the doctor's prescription medicine was ₩1,000, and the pharmacist makes generic substitution with a low-cost ₩700 medicine, he will be offered ₩90, which is 30% of the difference in drug prices (₩300).

 

Pharmacists can substitute medicines that are the same active ingredients, and are cheaper than those prescribed by doctors or dentists.

 

In the case of syrup, etc.

 

according to the maintenance of the drug benefit list from January 2016, the main ingredient code and representative code should be checked as the main ingredient code changes according to the production standard (total content).

 

The review was postponed once at a welfare committee meeting in April after the proposed amendment to the Pharmaceutical Law, which allows doctors, dentists or the HIRA to make post-notifications at the National Assembly to revitalize the Generic infrastructure.

 

The Health and Medical Development Council, which participates in the government and medical organizations, is preparing a plan to utilize the generic substitution post-notification DUR system.